Satheesh Kumar Nukala

Satheesh Kumar Nukala

Auto-generated profile, based on publicly available information

Satheesh Kumar Nukala

Department of Chemistry, Government Junior College, Mustabad, Rajanna Sircilla-505404, India

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2022 in ChemistrySelect
Verified
Journal Article
Closed access
AMAnnapurna Mamidala
Annapurna Mamidala
KBKarthik Bokkala
Karthik Bokkala
NTNarasimha Swamy Thirukovela
Narasimha Swamy Thirukovela
NSNarsimha Sirassu
Narsimha Sirassu
SBSrinivas Bandari
Srinivas Bandari
SNSatheesh Kumar Nukala
Satheesh Kumar Nukala

7 January 2024 in ChemistrySelect
Verified
Journal Article
Closed access
KBKarthik Bokkala
Karthik Bokkala
ABAshok Kumar Bapuram
Ashok Kumar Bapuram
NTNarasimha Swamy Thirukovela
Narasimha Swamy Thirukovela
SNSatheesh Kumar Nukala
Satheesh Kumar Nukala

19 June 2023 in ChemistrySelect
Verified
Journal Article
Closed access
AVAdvaitha Vanaparthy
Advaitha Vanaparthy
KBKarthik Bokkala
Karthik Bokkala
NTNarasimha Swamy Thirukovela
Narasimha Swamy Thirukovela
NSNarsimha Sirassu
Narsimha Sirassu
RMRavinder Manchal
Ravinder Manchal
SNSatheesh Kumar Nukala
Satheesh Kumar Nukala

31 December 2025 in Asian Journal of Chemistry
Verified
Journal Article
Open access
PDF file
SMSaidi Reddy Modugu
Saidi Reddy Modugu
GDGouthami Dasari
Gouthami Dasari
SNSatheesh Kumar Nukala
Satheesh Kumar Nukala
ABAshok Kumar Bapuram
Ashok Kumar Bapuram
RMRaju Mannoori
Raju Mannoori
BSBandari Srinivas
Bandari Srinivas
In this work, the synthesis of novel 1,2,3-triazolo-pyrano-quinazoline conjugates (6a-n) using well-known copper-catalyzed CuAAC and C-H arylation cascade reactions is carried out. The anticancer activity of these conjugates was evaluated against two human cancer cell lines, MCF-7 and HepG-2. The results showed that conjugate 6e exhibited more potent activity compared to the standard drug erlotinib, while compounds 6b, 6d and 6f displayed slightly lower activity compared to the standard drug. These four potent compounds (6b, 6d, 6e and 6f) were assessed in a cell survival assay employing the normal breast cell line MCF-10A. None of them showed significant cytotoxicity, with IC50 values larger than 98.20 µM. In vitro tyrosine kinase EGFR inhibitory of four potent compounds were evaluated and results indicate that compound 6e exhibited higher EGFR inhibitory activity compared to the standard drug erlotinib. On the other hand, compounds 6b and 6f displayed lower activity compared to both the standard drug and compound 6e. Furthermore, the molecular docking studies were also performed on four potent conjugates and the results showed that these conjugates had more EGFR-binding interactions as compared to the standard drug erlotinib. Moreover, the in silico pharmacokinetic outline of the potent conjugates 6b, 6d, 6e and 6f was estimated by using SWISS/ADME and pkCSM and all the four conjugates followed Lipinski rule of five, Ghose, Veber, Egan and Muegge rules without any deviation.

30 November 2025 in Asian Journal of Chemistry
Verified
Journal Article
Open access
PDF file
VLVeeraboina Lingaswamy
Veeraboina Lingaswamy
RKRaja Shekhar Kondrapolu
Raja Shekhar Kondrapolu
ABAshok Kumar Bapuram
Ashok Kumar Bapuram
SNSatheesh Kumar Nukala
Satheesh Kumar Nukala
RMRavinder Manchal
Ravinder Manchal
In this work, new hybrid compounds (7a-o) embedded with indole, thiazolidinedione and 1,2,3-triazole pharmacophores using Cu(I) catalyzed azide alkyne cycloaddition as key approach were synthesized and characterized. All these compounds were tested for their in vitro anticancer activity against three human cancer cell lines such as A549, MCF-7 and HeLa and nocodazole was used as reference drug. Compounds 7a, 7c, 7g, 7l and 7n have shown predominant activity than nocodazole towards three cell lines with IC50 values ranging from 0.3 to 1.37 µM. These five potent compounds were further screened for in vitro tubulin polymerization inhibition assay, where compounds 7c, 7g, 7l and 7n exhibited more inhibition than the standard drug combretastatin A4 (CA-4). In in silico molecular docking studies all these five compounds displayed remarkable binding energies with target protein α,β-tubulin (PDB ID: 1SA0). Further, results of in silico ADMET of the same five compounds revealed that they followed Lipinski rule, Veber rule, Egan rule and Muegge rules without any deviation and lipophilicity (Log Po/w) of the compounds was ranging from 2.80 to 4.06. Finally, compound 7n was characterized using density functional theory (DFT) with B3LYP/6–311++G (d,p) basis set.

1 January 2005
Verified
Book Chapter
Closed access
MPM. Periasamy
M. Periasamy
MRMandadi Narsimha Reddy
Mandadi Narsimha Reddy
NKN. S. Kumar
N. S. Kumar
Science of Synthesis is your online synthetic methodology tool for the most reliable chemical transformations available!